ERBB2 and breast cancer: Most CAR-NKs developed so far were tested in hematological malignancies, and some clinical trials are currently evaluating the safety and efficacy of PD-L1 or HER2-targeting CAR-NK therapy in solid tumors, although, to the best of our knowledge, there is not published data on human trials on BC up to now (186).